Erasca, Inc. research snapshot
ERAS AI stock analysis currently reads Erasca, Inc. as a clinical-stage precision oncology company singularly focused on shutting down the RAS/MAPK pathway, one of cancer most commonly mutated signaling cascades. ERAS closed at $18.53 on July 10, 2026, implying a calculated market value of about $5.76 billion using about 311 million shares. The company has no approved products or revenue, reported a TTM net loss of approximately $277 million, used about $213 million in free cash flow, and held roughly $244 million in cash at the most recent balance sheet date. The central ERAS AI stock forecast question is whether its pan-RAS molecular glue ERAS-0015 and broader pipeline can produce clinical proof of concept and regulatory value before cash burn, dilution, IP litigation with Revolution Medicines, and class action lawsuits consume the current equity value. This is informational research, not investment advice.
Current price
$18.53 close on July 10, 2026
Market cap
$5.76 billion intraday from Yahoo Finance, calculated from $18.53 x 310.985 million shares; Barchart confirmed $5.76B
AI score
35 / 100
Rating
Clinical-stage precision oncology platform with an experienced management team and a broad RAS/MAPK pipeline, but pre-revenue, loss-making, facing patent litigation and class action lawsuits, and priced for significant pipeline success
Trend status
Above the 20-day, 50-day, and 200-day averages after a massive YTD rally from $1.33, but the April 2026 collapse of 48% followed by class action litigation adds structural uncertainty
Data cutoff (updated weekly)
July 12, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Erasca is a clinical-stage biotech with no approved products or revenue. The business quality is unproven. Scientific approach targeting RAS/MAPK is well grounded, but commercial quality cannot be assessed without approved products and operating history. | Low |
| Moat | The moat is potential only. Erasca has intellectual property around pan-RAS molecular glues, licensed programs, and an experienced discovery team. However, Revolution Medicines has challenged Erasca IP, and the RAS-targeting space is crowded with well-funded competitors including Revolution Medicines, BridgeBio, and others. | Low |
| Management | Jonathan Lim is a proven founder who led Ignyta to a Roche acquisition and has generated billions in prior shareholder value. The management team includes senior leaders from Genentech, Pfizer, and GSK. Capital allocation discipline will be tested by cash burn and the need for future financing. | Medium |
| Financial trend | Erasca has no revenue and reports significant net losses. TTM net loss was approximately $277 million and free cash flow was negative $213 million. Cash and investments of about $244 million provide limited runway given the current burn rate and the need to fund multiple clinical programs. | Medium |
| Valuation | At $18.53, the exact valuation check produced negative TTM P/E of 19.92x, 14.59x book value, and negative P/FCF of 27.25x. These ratios are not conventional value signals because earnings and cash flow remain deeply negative. The market cap of $5.76B prices in substantial pipeline probability. | High |
| Technical trend | The stock has rallied 398% YTD from $1.33 to $18.53, far above the 50-day and 200-day averages. The April 2026 collapse from $24.28 to about $12.60 (48% decline) was followed by a recovery to $18.53. RSI crossed below 70 in mid-July, suggesting overbought conditions are easing. | Medium |
| Risk level | Risk is very high. Erasca faces binary clinical risk for ERAS-0015, IP litigation with Revolution Medicines, a securities class action lawsuit, no product revenue, limited cash runway relative to burn rate, potential dilutive financing, and the inherent uncertainty of early-stage drug development. | High |
| AI confidence | The reported financial and market data are well supported. Confidence is lower for pipeline probability, regulatory outcomes, litigation resolution, cash runway, and forward price scenarios. | Low-medium |
| Investment certainty | Investment certainty is very low. Erasca research view is a high-risk, high-uncertainty clinical-stage biotech where the current market cap of $5.76B already prices in meaningful pipeline success. A clinical setback, adverse litigation outcome, or dilutive financing could reduce equity value substantially. | Very low |
ERAS AI stock forecast
The ERAS AI stock forecast is a scenario range, not a point target. StockAnalysis listed an 11-analyst average price reference of $21.00, but analyst targets are not company guidance and can change quickly. The required financial_rigor.py three-scenario calculation used negative TTM EPS of $0.93 and produced mechanically negative reference values that are not decision-useful for a loss-making preclinical biotech. The practical ranges below focus on pipeline execution, IP litigation, cash runway, clinical data, and market multiple risk.
$25 to $35 scenario range
More likely if ERAS-0015 Phase 1/2 data show meaningful clinical activity and safety, the Revolution Medicines IP challenge is resolved favorably or settled on reasonable terms, class action lawsuits are dismissed or settled without material liability, and the company raises capital on favorable terms or signs a partnership that validates the platform.
$12 to $25 scenario range
More likely if ERAS-0015 data are adequate but not transformative, IP litigation creates ongoing uncertainty, cash burn continues at the current pace requiring dilutive financing within 12 to 18 months, and the market prices the stock within a wide pre-revenue biotech range.
$4 to $12 scenario range
More likely if ERAS-0015 clinical data disappoint or reveal safety concerns, Revolution Medicines wins a significant IP ruling, class action lawsuits result in material settlement costs, the $258.8M stock offering is followed by additional dilutive financing at unfavorable prices, or the company misses key pipeline milestones.
ERAS AI technical analysis
ERAS AI technical analysis uses the July 10, 2026 close of $18.53 and the latest available technical data. The stock has rallied from a 52-week low of $1.33 to $18.53, putting it well above all major moving averages. The April 2026 collapse from $24.28 created a wide trading range. Barchart technical opinion at last check was 88% Buy with RSI crossing below 70 from overbought territory, suggesting a potential mean reversion. These are reference levels, not trading instructions.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $18.53 | Official Erasca stock data shows the July 10 close, a high of $19.14, a low of $18.11, and volume of 2,933,525 shares (below the 7M average). |
| Immediate support reference | $17.92 to $18.11 | The July 10 low and the June 25 close from the 20-day price history define the nearest price-action zone. A break below it would show continued short-term weakness. |
| Intermediate support reference | $13.38 to $15.08 | The June 11 low and the June 17 close define a zone that was tested during the post-offering recovery. A move below these levels would suggest a deeper correction. |
| Near resistance reference | $19.14 to $20.08 | The July 10 high and the July 9 high ($20.08) define the immediate recovery zone. A sustained break above $20.08 would need volume and clinical or partnership confirmation. |
| Major resistance reference | $24.28 | The 52-week high set on April 23, 2026, before the collapse. This is the all-time high and a major psychological resistance level. |
| Moving averages | 20-day, 50-day, and 200-day all well below current price | Given the massive YTD rally from $1.33 to $18.53, all major moving averages are well below the current price. Specific levels should be refreshed from current chart data before use. |
| Momentum | RSI crossed below 70 from overbought territory | Barchart technical opinion noted the overbought condition was easing in mid-July. Momentum should be recalculated from current data before any decision. |
| Volume and volatility | 2.93M shares on July 10; 20-day average about 7.0M; implied volatility 103.73% | Volume on July 10 was below the 20-day average. Implied volatility of 103.73% reflects high options market expectations for continued event-driven movement. Clinical data, litigation news, and financing events can create gaps larger than ordinary daily volatility. |
| Invalidation reference | Sustained close below $13.38 | A sustained close below the June 11 low ($13.38) would weaken the post-collapse recovery structure. A clinical or litigation adverse event can invalidate technical levels immediately. |
ERAS AI trading strategy
The ERAS AI trading strategy is a rules-based research framework, not personalized advice. Use a live chart, a clinical trial calendar, current filings, litigation updates, position sizing, and a plan for overnight gaps because clinical and litigation catalysts can overwhelm ordinary stops.
Wait for price to reclaim and sustain above the $19.14 to $20.08 resistance zone with volume above the 7M average, then confirm that a clinical data release, partnership announcement, or favorable litigation development supports the move. A breakout without a fundamental catalyst is only a price signal.
A failed breakout followed by a close below $17.92 weakens the short-term setup. A sustained close below $13.38 is a broader trend warning.
If price holds the $17.92 to $18.11 zone, monitor ERAS-0015 data timelines, cash runway, IP litigation status, and class action developments. The setup tests whether the pullback is technical rather than a change in pipeline or litigation probability.
Do not average down only because price reaches a historical level. Reassess after an adverse clinical outcome, unfavorable IP ruling, class action settlement, financing event, or a material change in pipeline probability.
Track ERAS-0015 Phase 1/2 clinical data releases, Revolution Medicines IP litigation milestones, class action lawsuit status, cash runway and financing needs, naporafenib development progress, partnership or collaboration announcements, and competitor developments in the RAS/MAPK space.
Lower confidence if ERAS-0015 data are weak, IP litigation goes against Erasca, cash burn accelerates, new equity is issued at an unfavorable price, or class action lawsuits result in material financial liability.
Investment research summary
Erasca aims to discover, develop, and commercialize therapies that shut down the RAS/MAPK pathway, which is mutated in approximately 5.5 million new cancer cases per year globally. The company pipeline includes ERAS-0015 (pan-RAS molecular glue), ERAS-4001 (pan-KRAS inhibitor), ERAS-12 (EGFR biparatopic antibody), and naporafenib (licensed from Novartis). With no approved products or revenue, Erasca is currently a pipeline story where value depends entirely on clinical execution, regulatory outcomes, and partnering. Buffett-style question: would this remain a good business if the pipeline stopped advancing?
Erasca potential moat rests on intellectual property around pan-RAS molecular glues, drug discovery expertise, and early-mover positioning in the RAS degrader space. The moat is weakened by the Revolution Medicines IP challenge, the crowded RAS-targeting competitive landscape (Revolution Medicines, BridgeBio, Amgen, Mirati/BMS), and the fact that most pipeline assets are in preclinical or Phase 1 development. There are no switching costs, network effects, or brand advantages yet. Buffett-style question: which part of the moat would still exist ten years after a better-funded competitor entered?
The failure paths are numerous and individually sufficient. ERAS-0015 may show insufficient clinical activity or safety signals in Phase 1/2. Revolution Medicines may win a significant IP ruling that limits or blocks Erasca programs. The class action lawsuits may result in substantial settlement costs or distract management. At the current burn rate, cash may run out within approximately 12-18 months without additional financing, likely dilutive. Even successful clinical development does not guarantee commercial success, as RAS pathway inhibition has historically been difficult and competitors are well capitalized. Munger-style question: what fact would make the current valuation look obviously too optimistic?
Jonathan Lim (Chairman, CEO and Co-founder) has a strong track record as a biotech founder, having led Ignyta to a Roche acquisition and generated approximately $10 billion in cumulative shareholder value across prior ventures. The management team includes veterans from Genentech, Pfizer, GSK, and other major pharma, with deep oncology drug development experience. However, the capital allocation picture is challenged: the company raised $258.8 million in an offering that preceded a 53.9% stock collapse, and the current cash balance of about $244 million provides limited runway against a burn rate that consumed $213 million in free cash flow over the TTM period. Dilution risk is material. Management question: if the CEO left, would the scientific and clinical system still deliver?
RAS/MAPK pathway targeting represents one of the most important frontiers in precision oncology. KRAS was considered undruggable for decades until Amgen Lumakras and Mirati Krazati breakthroughs, and the field is now rapidly expanding into pan-RAS approaches, RAS degraders, and combination strategies. The TAM is enormous: approximately 5.5 million new annual cancer cases globally involve RAS/MAPK pathway mutations. Erasca is positioned at the discovery and early clinical layer of this trend, with the opportunity to create first-in-class pan-RAS therapies. The ceiling is bounded by clinical execution, competition from well-capitalized peers, manufacturing scalability, and pricing and reimbursement dynamics. Li Lu-style question: in twenty years, will pan-RAS therapy be a durable oncology standard or will multiple competing modalities dominate the space?
At $18.53, the calculated equity value is about $5.76 billion against zero revenue and negative earnings. The exact check produced negative TTM P/E of 19.92x, 14.59x book value, and negative P/FCF of 27.25x. The price depends entirely on future pipeline value. The three-scenario model is not decision-useful because EPS is negative. The margin of safety is minimal for a pre-revenue biotech where clinical, IP litigation, class action, and financing risks are all unresolved. Buffett-style question: if the market closed for five years, would the current price be justified by the cash flows the business can reasonably produce?
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| ERAS closing price and session range | $18.53 close on July 10, 2026; high $19.14; low $18.11; volume 2,933,525 | Yahoo Finance historical data and Barchart | July 12, 2026 |
| Market cap and shares | $5.76B intraday from Yahoo Finance; 310.985M shares outstanding from Barchart; calculated $18.53 x 310.985M = $5.76B confirmed by financial_rigor.py | Yahoo Finance, Barchart, and financial_rigor.py market-cap check | July 12, 2026 |
| TTM financial results | Zero revenue; approximately $277M net loss; approximately $213M negative free cash flow | Yahoo Finance key statistics (Net Income TTM, Levered Free Cash Flow TTM) | July 12, 2026 |
| Cash and balance sheet | Approximately $244M total cash (mrq); debt/equity ratio 11.68% | Yahoo Finance statistics and Barchart fundamentals | July 12, 2026 |
| Valuation ratios | Negative TTM P/E 19.92x; P/B 14.59x; negative P/FCF 27.25x; ROE negative 73.23% | financial_rigor.py verify-valuation command with Yahoo Finance inputs | July 12, 2026 |
| Analyst ratings and target | Strong Buy consensus from 11 analysts; average price target $21.00; range $12.00 to $30.00 | Yahoo Finance analysis section and Barchart analyst ratings | July 12, 2026 |
| 52-week price range | $1.33 low on September 3, 2025; $24.28 high on April 23, 2026 | Yahoo Finance statistics and Barchart price performance | July 12, 2026 |
| Beta and volatility | Beta 0.67; implied volatility 103.73%; 20-day average volume approximately 7.0M shares | Yahoo Finance and Barchart options and statistics | July 12, 2026 |
| Pipeline status | ERAS-0015 (pan-RAS molecular glue) in Phase 1/2; ERAS-4001 (pan-KRAS inhibitor) in preclinical; ERAS-12 (EGFR biparatopic antibody) in preclinical; naporafenib (pan-RAF, licensed from Novartis) in Phase 2 | Erasca corporate website pipeline page | July 12, 2026 |
| Recent litigation events | Stock dropped 48% on April 27-28, 2026 after Revolution Medicines accused Erasca of IP theft; $258.8M stock offering preceded the collapse; multiple securities class action lawsuits filed in July 2026 | Public SEC filings, press releases, and news coverage | July 12, 2026 |
| Enterprise value | Approximately $5.56B (Yahoo Finance) | Yahoo Finance key statistics | July 12, 2026 |
| Technical snapshot | RSI crossed below 70 in mid-July; Barchart technical opinion 88% Buy; above all major moving averages | Barchart technical opinion and indicators | July 12, 2026 |
This ERAS AI stock analysis page is an informational research tool, not investment advice, a recommendation, or a promise of returns. Forecast ranges are scenario outputs based on available data and assumptions that can be wrong. Verify current prices, filings, clinical and regulatory updates, litigation status, technical levels, tax rules, and personal suitability before making any financial decision.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
